{"id":459559,"date":"2026-03-22T04:29:19","date_gmt":"2026-03-22T04:29:19","guid":{"rendered":"https:\/\/www.europesays.com\/es\/459559\/"},"modified":"2026-03-22T04:29:19","modified_gmt":"2026-03-22T04:29:19","slug":"medicamento-farmaco-tumores-neuroendocrinos-el-axitinib-el-medicamento-que-logra-frenar-el-avance-de-tumores-neuroendocrinos","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/es\/459559\/","title":{"rendered":"MEDICAMENTO F\u00c1RMACO TUMORES NEUROENDOCRINOS | El axitinib, el medicamento que logra frenar el avance de tumores neuroendocrinos"},"content":{"rendered":"

Un ensayo internacional de fase III, AXINET, que lidera el\u00a0hospital p\u00fablico 12 de Octubre<\/strong>\u00a0de la\u00a0Comunidad de Madrid<\/a>, ha revelado la eficacia de un nuevo f\u00e1rmaco, el axitinib,\u00a0frente a tumores neuroendocrinos extrapancre\u00e1ticos\u00a0<\/strong>metast\u00e1sicos, logrando frenar su avance. Combinado con el tratamiento est\u00e1ndar, el octre\u00f3tido, los datos\u00a0muestran una mejora significativa de la respuesta<\/strong>\u00a0y el control de la enfermedad, explican desde el centro sanitario.<\/p>\n

\"Espa\u00f1oles<\/a><\/p>\n

Dossier CV<\/p>\n

21\/3\/2026, 21:19:31<\/p>\n

21\/3\/2026, 21:19:31\"Abascal:<\/a><\/p>\n

CUMBRE ULTRACONSERVADORA<\/p>\n

21\/3\/2026, 18:49:16<\/p>\n

21\/3\/2026, 18:49:16\"Felipe<\/a><\/p>\n

F\u00d3RMULA E MADRID<\/p>\n

21\/3\/2026, 18:11:59<\/p>\n

21\/3\/2026, 18:11:59\"El<\/a><\/p>\n

DECRETO ANTICRISIS<\/p>\n

21\/3\/2026, 17:19:00<\/p>\n

21\/3\/2026, 17:19:00 <\/p>\n","protected":false},"excerpt":{"rendered":"Un ensayo internacional de fase III, AXINET, que lidera el\u00a0hospital p\u00fablico 12 de Octubre\u00a0de la\u00a0Comunidad de Madrid, ha…\n","protected":false},"author":2,"featured_media":14511,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[92],"tags":[7377,94707,1066,119,2053,25,24,7116,165,11812,205,31622,14352,1421,166,23,1077],"class_list":["post-459559","post","type-post","status-publish","format-standard","has-post-thumbnail","category-salud","tag-avance","tag-axitinib","tag-cancer","tag-ciencia","tag-ensayo","tag-es","tag-espana","tag-frenar","tag-health","tag-logra","tag-madrid","tag-medicamento","tag-pi-videos","tag-publico","tag-salud","tag-spain","tag-tumores"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@es\/116270947822409604","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/es\/wp-json\/wp\/v2\/posts\/459559","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/es\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/es\/wp-json\/wp\/v2\/comments?post=459559"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/es\/wp-json\/wp\/v2\/posts\/459559\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/es\/wp-json\/wp\/v2\/media\/14511"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/es\/wp-json\/wp\/v2\/media?parent=459559"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/es\/wp-json\/wp\/v2\/categories?post=459559"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/es\/wp-json\/wp\/v2\/tags?post=459559"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}